Apellis Pharmaceuticals (APLS) and Swedish Orphan Biovitrum AB Report Publication of Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in hemoglobin levels and showed improvements in key clinical outcomes

Marketing applications for pegcetacoplan are under Priority Review with the FDA and under review with the EMA

WALTHAM, Mass. and STOCKHOLM, March 17, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) today announced that... More